Efficacy and safety of a 4-month quabodepistat, delamanid, and bedaquiline regimen for drug-susceptible pulmonary tuberculosis: a multicentre, open-label, randomised, proof-of-concept, non-inferiority, phase 2b/c trial. (linkinghub.elsevier.com)

Authors: Dawson R … Hafkin J Journal: Lancet Infectious Diseases Published: 2026-05-29 DOI: https://doi.org/10.1016/S1473-3099(26)00143-X